Favourable one-year ART outcomes in adult Malawians with hepatitis B and C co-infection

Journal of Infection

Volumn 61, Issue 2, 2010, Pages 155-163

  Moore, E ^a   Beadsworth, M B J ^a,b   Chaponda, M ^a,b   Mhango, B ^a   Faragher, B ^b   Njala, J ^a   Hofland, H W C ^a   Davies, J ^b   Hart, I J ^b   Beeching, N J ^b   Zijlstra, E E ^a   van Oosterhout, J J ^a  

^a UNIVERSITY OF MALAWI   (Malawi)

^b ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

ART; Hepatitis B and C; Hepatotoxicity; HIV; Malawi

Indexed keywords

AMITRIPTYLINE; ANTIRETROVIRUS AGENT; FLUCONAZOLE; GRISEOFULVIN; HISTAMINE H2 RECEPTOR ANTAGONIST; METHYLDOPA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ABDOMINAL PAIN; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; JAUNDICE; LACTIC ACIDOSIS; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALAWI; MALE; MIXED INFECTION; MORBIDITY; MORTALITY; NAUSEA; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PROSPECTIVE STUDY; SIDE EFFECT; TUBERCULOSIS; VOMITING; COMPLICATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; PREGNANCY; TREATMENT OUTCOME;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; FEMALE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HIV INFECTIONS; HIV-1; HUMANS; MALAWI; MALE; PREGNANCY; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 77955050489     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2010.04.009     Document Type: Article

References (43)

1. Gilson R.J., Hawkin A.E., Beecham M.R., Ross E., Waite J., Briggs M., et al. Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection. AIDS 1997, 11:587-606.
2. Puoti M., Torti C., Bruno R., Filice G., Carosi G. Natural history of chronic hepatitis B in coinfected patients. J Hepatol 2006, 44:S65-70.
3. Graham C.S., Baden L.R., Yu E., Mrus J.M., Carnie J., Heerlen T., et al. Influence of Human Immunodeficiency Virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001, 33:562-569.
4. Omland L.H., Jepson P., Skinhoj P., Jørgensen H.L., Münster A.M., Bangsborg J., et al. The impact of HIV-1 co-infection on long-term mortality in patients with hepatitis C: a population-based cohort study. HIV Med 2009, 10:65-71.
5. Thio C.L., Seaberg E.C., Skolasky R., Phair J., Visscher B., Munoz A., et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicentre Cohort Study (MACS). Lancet 2002, 360:1921-1926.
6. Greub G., Ledergerber B., Battergay M., Grob P., Perrin L., Furrer H., et al. Clinical progression, survival and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000, 356:1800-1805.
7. Hoffman C.J., Seaberg E.C., Young S., Witt M.D., D'Acunto K., Phair J., et al. Hepatitis B and long-term HIV outcomes in coinfected HAART recipients. AIDS 2009, 23:1881-1889.
8. Farmer-Millar M., Haley C., Koziel M.J., Rowley C.F. Impact of Hepatitis C on immune restoration in HIV-infected patients who start highly active antiretroviral therapy: a meta-analysis. Clin Infect Dis 2005, 41:713-720.
9. Sheng W.H., Chen M.Y., Hsieh S.M., Hsiao C.F., Wang J.T., Hung C.C., et al. Impact of chronic hepatitis B virus (HBV) infection on outcomes of patients with HIV in an area where HBV infection is hyperendemic. Clin Infect Dis 2004, 38:1471-1477.
10. Law W.P., Duncombe C.J., Mahanontharit A., Boyd M.A., Ruxrungtham K., Lange J.M., et al. Impact of viral hepatitis coinfection on response to antiretroviral therapy and HIV disease progression in HIV-NAT Cohort. AIDS 2004, 18:1169-1177.
11. Sulkowski M.S., Thomas D.L., Mehta S.H., Chaisson R.E., Moore RDl Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002, 35:182-189.
12. den Brinker M., Wit F.W.N.M., Wertheim-van Dillen P.M.E., Jurriaans S., Weel J., van Leeuwen R., et al. Hepatitis B and C virus coinfection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 2000, 14:2895-2902.
13. Sulkowski M.S., Thomas D.L., Chaisson R.E., Moore R.D. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. J Am Med Assoc 2000, 283:74-80.
14. Law W.P., Dore G.J., Duncombe C.J., Boyd M.A., Ruxrungtham K., Lange J.M., et al. Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001. AIDS 2003, 17:2191-2199.
15. Hoffmann C.J., Thio C.L. Clinical implications of HIV and hepatitis B coinfection in Asia and Africa. Lancet Infect Dis 2007, 7:402-409.
16. Nyirenda M., Beadsworth M.B.J., Stephany P., Haart C.A., Hart I.J., Munthali C., et al. Prevalence of infection with hepatitis B and C virus and coinfection with HIV in medical inpatients in Malawi. J Infect 2008, 57:72-77.
17. Candotti D., Mundy C., Kadewele G., Nkhoma W., Bates I., Allain J.P. Serological and molecular screening for viruses in blood donors from Ntcheu, Malawi: high prevalence of HIV-1 subtype C and of markers of Hepatitis B and C viruses. J Med Virol 2001, 65:1-5.
18. Sutcliffe S., Taha T.E., Kumwenda N.I., Taylor E., Liomba GNl HIV-1 prevalence and herpes simplex virus 2, hepatitis C virus and hepatitis B virus infections among male workers at a sugar estate in Malawi. J Acquir Immune Defic Syndr 2002, 31:90-97.
19. van Leth F., Phanuphak P., Ruxrungtham K., Balardi E., Miller S., Gazzard B., et al. Comparison of first line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and Lamivudine: a randomised open-label trial, the 2 NN study. Lancet 2004, 363:1253-1263.
20. Martinez E., Blanco J.L., Arnaiz J.A., Perez-Cuevas J.B., Mocroft A., Cruceta A., et al. Hepatotoxicity in HIV-1 infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 2001, 15:1261-1268.
21. Freiman J., Helfert K., Hamrell M., Stein D.S. Hepatomegaly with severe steatosis in HIV-seropositive patients. AIDS 1993, 7:379-385.
22. Dore G.J., Cooper D.A., Barrett C., Goh L.E., Thakrar B., Atkins M. Dual efficacy of lamivudine treatment in HIV/ hepatitis B virus coinfected persons in a randomised, controlled study (CAESAR). J Infect Dis 1999, 180:607-613.
23. Benhamou Y., Bochet M., Thibault V., Di Martino V., Caumes E., Bricaire F., et al. Long-term incidence of hepatitis B virus resistance to lamivudine in HIV infected patients. Hepatology 1999, 30:1302-1306.
24. Bessesen M., Ives D., Condreay L., Lawrence S., Sherman K.E. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. Clin Infect Dis 1999, 28:1032-1035.
25. Mortality of HIV-1 infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006, 367:817-824. ART-LINC collaboration.
26. Lawn S.D., Myer L., Orrell C., Bekker L.G., Wood R. Early mortality among adults accessing a community based antiretroviral service in South Africa: implications for program design. AIDS 2005, 19:2141-2148.
27. Marazzi M.C., Liotta G., Germano P., Guidotti G., Altan A.D., Ceffa S., et al. Excessive early mortality in the first year of treatment in HIV-1 infected patients initiating antiretroviral therapy in resource-limited settings. AIDS Res Hum Retroviruses 2008, 24:555-560.
28. National Statistics Office of Malawi. HIV prevalence and associated factors; 2004.
29. Schnuriger A., Dominguez S., Valantin M.A., Tubiana R., Duvivier C., Ghosn J., et al. Early detection of hepatitis C virus infection by use of a new combined antigen-antibody detection assay: potential use for high-risk individuals. J Clin Microbiol 2006, 44:1561-1563.
30. Chamie G., Bonacini M., Bangsberg D.R., Stapleton J.T., Hall C., Overton E.T., et al. Factors associated with seronegative chronic hepatitis C virus infection in HIV infection. Clin Infect Dis 2007, 44:577-583.
31. Table for grading severity of adverse experiences 1992, AIDS Clinical Trial Group Criteria, Section 11, Division of AIDS, National Institute of Allergy & Infectious Diseases.
32. Hoffman C.J., Charalambous S., Martin D.J., Innes C., Churchyard G.J., Chaisson R.E., et al. Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program. Clin Infect Dis 2008, 47:1479-1485.
33. Hoffman J.H., Charalambous S., Thio C.L., Martin D.J., Pemba L., Fielding K.L., et al. Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. AIDS 2007, 21:1301-1308.
34. Idoko J., Meloni S., Muazu M., Nimzing L., Badung B., Hawkins C., et al. Impact of hepatitis B virus on human immunodeficiency virus response to antiretroviral therapy in Nigeria. Clin Infect Dis 2009, 49:1268-1273.
35. Bersoff-Matcha S.J., Miller W.C., Aberg J.A., van der Horst C., Hamrick H.C., Powderly W.G., et al. Sex differences and nevirapine rash. Clin Infect Dis 2001, 32:124-129.
36. Aranzabal L., Casado J.L., Moya J., Quereda C., Diz S., Moreno A., et al. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis 2005, 40:588-593.
37. Medina-Lara A, Kigozi J, Amurwon J, Muchabaiwa L, Nyanzi Wakholi B, Walker S, et al., Cost effectiveness analysis of routine laboratory or clinically driven strategies for monitoring antiretroviral therapy in Uganda and Zimbabwe (DART trial). In: 5th International AIDS society conference on HIV pathogenesis, treatment and prevention, Cape Town; 2009 [abstract TuSS104].
38. Podsadecki T.J., Vrijens B.C., Tousset E.P., Rode R.A., Hanna G.J. Decreased adherence to antiretroviral therapy observed prior to transient HIV type 1 viraemia. J Infect Dis 2007, 196:1773-1778.
39. Zacharia R., Fitzgerald M., Massaquoi M., Pasulani O., Arnould L., Makombe S., et al. Risk factors for high early mortality in patients on antiretroviral treatment in a rural district of Malawi. AIDS 2006, 20:2355-2360.
40. Castelnuovo B., Manabe Y.C., Kiragga A., Kamya M., Easterbrook P., Kambuga A. Cause-specific mortality and the contribution of immune reconstitution inflammatory syndrome in the first 3 years after antiretroviral therapy initiation in an urban African cohort. Clin Infect Dis 2009, 49:973-975.
41. Harania R.S., Karuru J., Nelson M., Stebbing J. HIV, hepatitis B and hepatitis C coinfection in Kenya. AIDS 2008, 22:1221-1222.
42. Malawi Ministry of Health Quarterly report National ART Programme, quarter ending 31 December 2007 2008, HIV Unit, Ministry of Health.
43. Elema R., Mills C., Yun O., Lokuge K., Ssonko C., Nyirongo N., et al. Outcomes of a remote, decentralized health centre-based HIV-AIDS antiretroviral program in Zambia, 2003-2007. J Int Assoc Physicians AIDS Care 2009, 8:60-67.